VioQuest Pharmaceuticals, Inc.’ Novel Akt Inhibitor VQD-002 is Synergistic with Various Cancer Therapies in Preclinical Studies

BASKING RIDGE, N.J.--(BUSINESS WIRE)--VioQuest Pharmaceuticals (OTCBB: VQPH) today announced preclinical data demonstrating that the company’s novel AKT inhibitor VQD-002 delivers synergistic benefit in combination with a range of cancer therapies including trastuzumab (Herceptin®; Genentech, Roche), dasatinib (Sprycel®; Bristol-Myers Squibb), cisplatin, and others. The results were presented in a series of poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.